Title:

Risk factors for gallstone disease onset in Japan: findings from the Shizuoka Study, a population-based cohort study

Author affiliations:

Kazuya Higashizono, M.D., Ph.D.^{1,2*}, Eiji. Nakatani, Ph.D.¹, Philip Hawke, M.A.³, Shuhei Fujimoto, Ph.D.¹ Noriyuki Oba, M.D., Ph.D.²

KH and EN contributed equally to this work.

¹ Graduate School of Public Health, Shizuoka Graduate University of Public Health, 4-27-2 Kitaando, Aoi-ku, Shizuoka, 420-0881, Japan.

² Department of Gastrointestinal Surgery, Shizuoka General Hospital, 4-27-1 Kitaando, Aoi-ku, Shizuoka, 420-8527, Japan.

³ School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

Contact information:

*Address correspondence to: Kazuya Higashizono Graduate School of Public Health, Shizuoka Graduate University of Public Health, 4-27-2 Kitaando, Aoi-ku, Shizuoka, 420-0881, Japan.

Phone: +81-54-247-6111, Fax: +81-54-247-6111

E-mail: toen0108@gmail.com

Abstract

In the research literature on factors associated with gallstones, large population-based cohort studies are rare. We carried out a study of this type to explore risk factors for the onset of gallstones. This study included Japanese participants aged 40-107 years who were followed prospectively from January 2012 to September 2020 using a dataset composed of two individually linked databases, one containing annual health checkup records and the other containing medical claims for beneficiaries of the National Health Insurance System and the Medical Care System for Elderly in the Latter Stage of Life in Shizuoka Prefecture, Japan. Among the 611,930 participants in the analysis set, 23,843 (3.9%) were diagnosed with gallstones during the observational period (median [max]: 5.68 [7.5] years). Multivariate analysis revealed that risk of gallstone disease was increased by male sex, cerebrovascular disease, any malignancy, dementia, rheumatic disease, chronic pulmonary disease, hypertension, and *H. pylori*-infected gastritis. These findings provide essential insights into the etiology of cholelithiasis and may contribute to efforts to reduce the incidence of the disease.

Keywords: gallstones, incidence, risk factors, health checkup, receipt database

INTRODUCTION

Gallstone disease, the condition of stones or sludge developing in the gallbladder or bile duct, is one of the most common gastrointestinal diseases [1]. Gallstones are associated with potential risk of cholecystitis, pancreatitis, biliary tract obstruction, and gallbladder cancer [2]. Gallstone-associated diseases often require cholecystectomy percutaneous/endoscopic biliary drainage due to late diagnosis and treatment of severe acute biliary inflammation/infection associated with sepsis and multiple organ failure. The reported mortality of acute cholangitis varies from 2.5% to 65% [3]. Therefore, elucidation of the risk factors for gallstones may help to prevent the onset of cholangitis, leading to increased life expectancy, reduction of medical costs, and improved social productivity.

Gallstones are composed of a mixture of cholesterol, calcium salts of bilirubinate or palmitate, proteins, and mucin. Based upon their predominant constituents, gallstones are broadly classified into cholesterol, brown pigment, and black pigment stones [4]. A variety of risk factors have been reported to be associated with gallstone formation. Established risk factors for the development of cholesterol gallstones due to enhanced cholesterol synthesis and secretion include genetic background and lifestyle, as well as internal disorders such as aging, female sex, pregnancy, obesity, rapid weight loss, diabetes mellitus, and dyslipidemia [5–10]. Predominant risk factors for pigment stones include liver dysfunction [11], Crohn's disease [12], and hyperbilirubinemia due to underlying genetic predisposition [13]. Spinal cord injury [14], prolonged fasting / parenteral nutrition [15], and gastrectomy [16] have also been reported to be risks for gallstone onset. Clinically, the incidence of gallstone disease has been increasing in the past decade in East Asia, coincident with increasing calorie and fat consumption, decreasing fiber intake, and increasing prevalence of sedentary lifestyle [17].

Despite the large number of previous epidemiological studies analyzing background factors related to gallstones, there have been few large-scale epidemiological studies, especially in East Asian countries. The aim of this study was to identify factors associated with the onset of gallstone disease in the healthy Japanese population, which can be assumed to reflect the characteristics of East Asians in general.

METHODS

Data source

The study was based on the Shizuoka Kokuho Database which is derived from a database providing the linked data of Federation of National Health Insurance Association (FNHIA) subscribers, including demographic and registration data, medical claims data, and health checkup data of enrollees in Shizuoka Prefecture [18]. Shizuoka Prefecture has a population of about 3.6 million people with climatic conditions and population distribution representative of Japan. The database represents 25% of the population under 65 and 75% of the population over 65 in the Prefecture, mainly due to it including individuals enrolled in the country's national health insurance programs (aged < 75, approximately 20% of all prefectural residents) and beneficiaries of late-stage elderly healthcare (aged \geq 75, all prefectural residents in the age group).

Japanese medical insurance and health checkup systems

Japan's medical system is based on a comprehensive insurance system. There are two types of health insurance for people aged < 75 years: Employee Health Insurance for the employees of government organizations and large companies, and National Health Insurance for small business owners and their employees. Health insurance for people aged \geq 75 years is provided by the Medical Care System for Elderly in the Latter Stage of Life.

The Japanese Ministry of Health, Labour and Welfare recommends annual health checkups for insured persons 40 year of age and older. These checkups focus especially on visceral fat obesity.

Study design, data availability period, and study population

The study scheme is shown in Figure 1. The study was analyzed as a retrospective cohort generated from the database. The dataset comprised 8.5 years of longitudinal data from April 2012 to September 2020. All enrollees were investigated using the individually linked data in the databases for their annual health checkups and their insurance claims.

Each enrollee's data availability period was defined as the time from the date of insurance registration or April 2012, whichever was later, to the date of insurance withdrawal or September 2020, whichever was earlier.

We excluded participants who received a diagnosis of gallstones before the start date of their health checkup, those who did not undergo a health checkup, and those whose observation period was < 1 year.

Onset of gallstone disease

Patients were classified as having gallstones when their insurance claims showed the code K80, which is listed in the International Classification of Diseases - 10th Revision (ICD-10) [19].

Covariates

For the variable of specific comorbidity, the one-year period prior to the date of the medical examination was used as the search period, and the variable was judged as being present if the disease had been recorded as confirmed in the insurance claims data. Variables likely to be associated with the development of cholelithiasis were similarly defined based on the ICD-10 list, with a search period of one year used to determine their presence or absence.

All of the health checkup data required for the study, including age, gender, height, weight, systolic and diastolic blood pressure, smoking habits, as well as the use of antihypertensive, lipid-lowering, and hypoglycemic drugs, was available in the form of self-reported questionnaire data.

Statistical analysis

The data was summarized as mean and standard deviation for continuous variables and as frequency and percentage for categorical variables. Univariable and multivariable Cox proportional hazards regression analyses were performed to explore factors associated with gallstone onset. Hazard ratio (HR), 95% confidence interval (CI), and P value were calculated, and a Wald test was conducted. Potential risk factors such as key etiological and epidemiological factors were examined using a regression analysis. Variables with a relatively large number of missing values in the health checkup data were excluded from

the multivariate model. One of two variables with high correlation was not used in the multivariate model owing to multicollinearity, based on the criterion of an absolute Spearman's correlation coefficient of > 0.4. As the missing covariates did not occur completely at random among all participants, a simple missing data imputation was not carried out. A P value of < .05 was considered statistically significant. All analyses were performed using the software packages EZR Version 1.27 (Saitama Medical Center, Jichi Medical University, Tochigi, Japan) and SAS Version 9.4 (SAS Institute Inc., Cary, NC,

Ethics

USA).

All enrollee data was anonymized by the Federation of National Health Insurance Association to protect participant confidentiality [18]. This study adhered to the principles of the Declaration of Helsinki and was approved by the Medical Ethics Committee of of Shizuoka Graduate School Public Health in Shizuoka. Japan (#SGUPH 2021 001 040).

RESULTS

Study population

Among the 2,654,567 individuals in the Shizuoka Kokuho Database, 741,009 underwent health checkups. Among these, 113,195 patients who had undergone an observation period of < 1 year and 15,884 who had already been diagnosed with gallstones were excluded. Data for the 611,930 remaining individuals was analyzed.

Gallstone disease onset

During the observation period (median [max]: 5.68 [7.5] years), 23,843 patients (3.9%) were newly diagnosed with gallstones. Among these, 4,759 (20.0%) had undergone cholecystectomy and percutaneous/endoscopic drainage. The baseline characteristics for the gallstone and other patients are shown in Table 1.

Table 1. Participant characteristics and variables for univariable Cox model analysis

Variable	Category or unit	Patients with gallstones N=23843	Other patients N=588087
Sex	Women	12797 (53.7)	335191 (57.0)
	Men	11046 (46.3)	252896 (43.0)
Age	0 to <40 years	41 (0.2)	4699 (0.8)
	40 to <50 years	620 (2.6)	44827 (7.6)
	50 to <60 years	1256 (5.3)	52581 (8.9)
	60 to <70 years	7779 (32.6)	222038 (37.8)
	70 to <80 years	8980 (37.7)	176696 (30.0)
	80 years to	5167 (21.7)	87246 (14.8)
Comorbidities			
Cerebrovascular disease	Presence	4262 (17.9)	73757 (12.5)
Any malignancy	Presence	2386 (10.0)	41148 (7.0)
Dementia	Presence	753 (3.2)	13749 (2.3)
Myocardial infarction	Presence	457 (1.9)	7897 (1.3)
Renal disease	Presence	660 (2.8)	11377 (1.9)
Rheumatic disease	Presence	721 (3.0)	13352 (2.3)
Liver disease	Presence	47 (0.2)	641 (0.1)
Congestive heart failure	Presence	2708 (11.4)	44666 (7.6)
Chronic pulmonary disease	Presence	5258 (22.1)	106453 (18.1)
Diabetes	Presence	1555 (6.5)	26978 (4.6)
Hypertension	Presence	13425 (56.3)	265039 (45.1)
Pylori-infected gastritis	Presence	1513 (6.3)	28545 (4.9)
History of gastrectomy	Presence	18 (0.1)	193 (0.0)
HIV infection	Presence	1 (0.0)	48 (0.0)
Crohn's disease	Presence	16 (0.1)	269 (0.0)
Spinal injury	Presence	1 (0.0)	18 (0.0)
Total parenteral nutrition	Presence	0 (0.0)	5 (0.0)
Medical checkup			
Frequency of alcohol consumption	Never	12178 (62.4)	296763 (59.2)
	Occasionally	3565 (18.3)	100302 (20.0)
	Everyday	3761 (19.3)	104269 (20.8)
Use of lipid-lowering agents	Yes	6818 (28.6)	139738 (23.8)
Current smoker	Yes	2392 (10.0)	69971 (11.9)
Walking or physical exercise > 1 h / wk	Yes	10510 (49.6)	267136 (50.5)
Increase in weight > 10 kg since age of 20 y	Yes	7348 (34.6)	154621 (29.2)
Estimated GFR	1 mL/min/1.73 m ²	66.42 (16.04)	69.47 (15.75)
BMI	1 kg/m ²	23.15 (3.55)	22.63 (3.43)
GGT	100 U/L	38.98 (66.47)	32.55 (45.30)
AST	10 U/L	25.66 (13.80)	24.05 (10.57)
ALT	10 U/L	21.59 (16.54)	20.17 (13.26)
HbA1c	1%	5.79 (0.73)	5.74 (0.70)
LDL cholesterol	10 mg/dL	120.76 (30.90)	124.02 (31.30)
Systolic blood pressure	10 mmHg	130.70 (16.59)	129.38 (17.36)
Triglycerides	100 mg/dL	118.60 (70.72)	113.92 (72.42)
Uric acid	1 mg/dL	5.35 (1.34)	5.22 (1.36)

HR, hazard ratio; CI, confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GFR, glomerular filtration rate; GGT, gamma-glutamyl transpeptidase; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Identification of risk factors of gallstone disease onset

Potential risk factors and significant variables were evaluated using a univariable Cox regression analysis (Table 2). Several variables had correlations of > 0.4 (S1 Table). Variables with p<0.05 in the univariable analysis were entered into the multivariable model.

Table 2. Results of univariable Cox model analysis

Sex (women) Men 1.21 1.18-1.24 <0.001	77 · 11 / 6	C 4 '4	Univariable Cox model		model
Age (0 to < 40 years) 40 to < 50 years 1.36 0.99-1.86 0.090 50 to < 60 years 1.98 1.45-2.71 <0.001 60 to < 70 years 2.62 1.93-3.56 <0.001 70 to < 80 years 3.65 2.69-4.96 <0.001 80 years and over 4.44 3.27-6.04 <0.001 Any malignancy (absence) Presence 1.49 1.44-1.54 <0.001 Any malignancy (absence) Presence 1.54 1.47-1.60 <0.001 Myocardial infarction (absence) Presence 1.60 1.49-1.72 <0.001 Myocardial infarction (absence) Presence 1.52 1.39-1.67 <0.001 Renal disease (absence) Presence 1.61 1.49-1.74 <0.001 Rheumatic disease (absence) Presence 1.61 1.49-1.74 <0.001 Liver disease (absence) Presence 2.03 1.52-2.70 <0.001 Congestive heart failure (absence) Presence 1.65 1.58-1.71 <0.001 Chronic pulmonary disease (absence) Presence 1.50 1.42-1.58 <0.001 H	variable (reference)	Category or unit	HR	95% CI	p value
50 to < 60 years 1.98 1.45-2.71 < 0.001	Sex (women)	Men	1.21	1.18-1.24	< 0.001
Cerebrovascular disease (absence)		40 to < 50 years	1.36	0.99-1.86	0.090
To to < 80 years 3.65 2.69-4.96 <0.001	3 /		1.98	1.45-2.71	< 0.001
So years and over		60 to < 70 years	2.62	1.93-3.56	< 0.001
Cerebrovascular disease (absence) Presence 1.49 1.44-1.54 <0.001 Any malignancy (absence) Presence 1.54 1.47-1.60 <0.001		70 to < 80 years	3.65	2.69-4.96	< 0.001
Any malignancy (absence) Presence 1.54 1.47-1.60 <0.001 Dementia (absence) Presence 1.60 1.49-1.72 <0.001		80 years and over	4.44	3.27-6.04	< 0.001
Dementia (absence)	Cerebrovascular disease (absence)	Presence	1.49	1.44-1.54	< 0.001
Myocardial infarction (absence) Presence 1.52 1.39-1.67 <0.001 Renal disease (absence) Presence 1.61 1.49-1.74 <0.001	Any malignancy (absence)	Presence	1.54	1.47-1.60	< 0.001
Renal disease (absence) Presence 1.61 1.49-1.74 <0.001 Rheumatic disease (absence) Presence 1.34 1.24-1.44 <0.001	Dementia (absence)	Presence	1.60	1.49-1.72	< 0.001
Renal disease (absence) Presence 1.61 1.49-1.74 <0.001 Rheumatic disease (absence) Presence 1.34 1.24-1.44 <0.001	Myocardial infarction (absence)	Presence	1.52	1.39-1.67	< 0.001
Liver disease (absence) Presence 2.03 1.52-2.70 <0.001 Congestive heart failure (absence) Presence 1.65 1.58-1.71 <0.001		Presence	1.61	1.49-1.74	< 0.001
Congestive heart failure (absence) Presence 1.65 1.58-1.71 <0.001 Chronic pulmonary disease (absence) Presence 1.29 1.25-1.33 <0.001	Rheumatic disease (absence)	Presence	1.34	1.24-1.44	< 0.001
Chronic pulmonary disease (absence) Presence 1.29 1.25-1.33 <0.001 Diabetes (absence) Presence 1.50 1.42-1.58 <0.001	Liver disease (absence)	Presence	2.03	1.52-2.70	< 0.001
Chronic pulmonary disease (absence) Presence 1.29 1.25-1.33 <0.001 Diabetes (absence) Presence 1.50 1.42-1.58 <0.001	Congestive heart failure (absence)	Presence	1.65	1.58-1.71	< 0.001
Diabetes (absence) Presence 1.50 1.42-1.58 <0.001 Hypertension (absence) Presence 1.51 1.47-1.54 <0.001	Chronic pulmonary disease (absence)		1.29	1.25-1.33	< 0.001
Hypertension (absence) Presence 1.51 1.47-1.54 <0.001 Pylori-infected gastritis (absence) Presence 1.29 1.22-1.36 <0.001	<u> </u>	Presence	1.50	1.42-1.58	< 0.001
Pylori-infected gastritis (absence) Presence 1.29 1.22-1.36 <0.001 History of gastrectomy (absence) Presence 2.22 1.40-3.52 <0.001				1.47-1.54	< 0.001
History of gastrectomy (absence) Presence 2.22 1.40-3.52 <0.001 HIV infection (absence) Presence 0.57 0.08-4.06 0.576 Crohn's disease (absence) Presence 1.61 0.98-2.62 0.058 Spinal injury (absence) Presence 1.60 0.23-11.37 0.637 Total parenteral nutrition (absence) Presence NE NE NE Frequency of alcohol consumption Never 1.00 0.87-0.93 <0.001	31 \ /	Presence	1.29	1.22-1.36	< 0.001
HIV infection (absence) Presence 0.57 0.08-4.06 0.576 Crohn's disease (absence) Presence 1.61 0.98-2.62 0.058 Spinal injury (absence) Presence 1.60 0.23-11.37 0.637 Total parenteral nutrition (absence) Presence NE NE NE Frequency of alcohol consumption Never 1.00 0.87-0.93 <0.001	<u> </u>	Presence	2.22	1.40-3.52	< 0.001
Crohn's disease (absence) Presence 1.61 0.98-2.62 0.058 Spinal injury (absence) Presence 1.60 0.23-11.37 0.637 Total parenteral nutrition (absence) Presence NE NE NE Frequency of alcohol consumption Never 1.00 0.87-0.93 <0.001		Presence	0.57	0.08-4.06	0.576
Total parenteral nutrition (absence) Presence NE NE NE Frequency of alcohol consumption Never 1.00	Crohn's disease (absence)	Presence	1.61		0.058
Total parenteral nutrition (absence) Presence NE NE NE Frequency of alcohol consumption Never 1.00	Spinal injury (absence)	Presence	1.60	0.23-11.37	0.637
Frequency of alcohol consumption Never Occasionally 1.00 0.90 0.87-0.93 0.801 <0.001 0.88-0.95 0.001 Lyse of lipid-lowering agents (no) Yes 0.83 0.81-0.86 0.001 <0.001 0.88-0.93 0.001		Presence	NE	NE	NE
Occasionally 0.90 0.87-0.93 <0.001 Everyday 0.91 0.88-0.95 <0.001		Never	1.00		
Everyday 0.91 0.88-0.95 <0.001 Use of lipid-lowering agents (no) Yes 0.83 0.81-0.86 <0.001		Occasionally	0.90	0.87-0.93	< 0.001
Use of lipid-lowering agents (no) Yes 0.83 0.81-0.86 <0.001 Current smoker (no) Yes 1.09 1.04-1.14 <0.001			0.91	0.88-0.95	< 0.001
Current smoker (no) Yes 1.09 1.04-1.14 <0.001 Walking or physical exercise > 1 h / wk Yes 0.91 0.88-0.93 <0.001	Use of lipid-lowering agents (no)	<u> </u>			
Walking or physical exercise > 1 h / wk Yes 0.91 0.88-0.93 <0.001					< 0.001
Yes 0.91 0.88-0.91 <0.001					
(no)	(no)	Yes	0.91	0.88-0.93	< 0.001
Increase in weight > 10 kg since age of		V	1.22	1.20, 1.27	-0.001
20 y (no) Yes 1.33 1.29-1.37 <0.001		Y es	1.33	1.29-1.3/	< 0.001
		1 mL/min/1.73 m ²	0.99	0.99-0.99	< 0.001
					< 0.001
· · · · · · · · · · · · · · · · · · ·					< 0.001
					< 0.001
					< 0.001
					< 0.001

LDL cholesterol	10 mg/dL	0.96	0.96-0.97	< 0.001
Systolic blood pressure	10 mmHg	1.04	1.03-1.05	< 0.001
Triglycerides	$100~\mathrm{mg/dL}$	1.10	1.08-1.12	< 0.001
Uric acid	1 mg/dL	1.07	1.06-1.07	< 0.001

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence interval; GFR, glomerular filtration rate; GGT, gamma-glutamyl transpeptidase; HbA1c, hemoglobin A1c; HR, hazard ratio; LDL, low-density lipoprotein.

The multivariable regression analysis showed that increasing age and male sex (HR: 1.09 [95% CI: 1.06-1.12]) increased the risk of gallstones (Table 3). The presence of comorbidities such as cerebrovascular disease (1.14 [1.10-1.19]), any malignancy (1.30 [1.24-1.36]), dementia (1.13 [1.04-1.23]), rheumatic disease (1.23 [1.14-1.33]), liver disease (1.56 [1.16-2.10]), congestive heart failure (1.17 [1.12-1.23]), chronic pulmonary disease (1.15 [1.12-1.19]), diabetes (1.15 [1.08-1.22]), hypertension (1.10 [1.06-1.13]), and H. pylori-infected gastritis (1.25 [1.18-1.32]) were also risks for the disease. Further, the health checkup data revealed that higher values for BMI (1.04 [1.04-1.05] per 1 kg/m² increase), GGT (1.15 [1.13-1.16] for 100 U/L increase), HbA1c (1.03 [1.01-1.04] per 1% increase), and triglycerides (1.04 [1.02-1.06] per 100 mg/dL increase) were associated with the onset of the disease. However, a habit of walking or other physical exercise > 1 h / week (0.91 [0.94-0.89]), higher LDL cholesterol (0.98 [0.98-0.99] per 10 mg/dL increase), and higher systolic blood pressure (0.98 [0.97-0.99] per 10 mmHg increase), were associated with reduced risk of gallstones.

Table 3. Results of multivariable Cox model analysis

Variable (reference),	Cotogowy on unit	Multivariable Cox model			
n=541,972, events=20,810	Category or unit	HR	95% CI	p value	
Sex (women)	Men	1.09	1.06-1.12	< 0.001	
Age (0 to < 40 years)	40 to < 50 years	1.31	0.95-1.81	0.103	
	50 to < 60 years	1.94	1.41-2.68	< 0.001	
	60 to < 70 years	2.54	1.85-3.48	< 0.001	
	70 to < 80 years	3.34	2.44-4.59	< 0.001	
	80 years and over	3.97	2.89-5.45	< 0.001	
Cerebrovascular disease (absence)	Presence	1.14	1.10-1.19	< 0.001	
Any malignancy (absence)	Presence	1.30	1.24-1.36	< 0.001	
Dementia (absence)	Presence	1.13	1.04-1.23	0.005	
Myocardial infarction (absence)	Presence	1.02	0.92-1.14	0.647	
Renal disease (absence)	Presence	1.14	1.05-1.24	0.003	
Rheumatic disease (absence)	Presence	1.23	1.14-1.33	< 0.001	
Liver disease (absence)	Presence	1.56	1.16-2.10	0.003	

Congestive heart failure (absence)	Presence	1.17	1.12-1.23	< 0.001
Chronic pulmonary disease (absence)	Presence	1.15	1.12-1.19	< 0.001
Diabetes (absence)	Presence	1.15	1.08-1.22	< 0.001
Hypertension (absence)	Presence	1.10	1.06-1.13	< 0.001
Pylori-infected gastritis (no)	Yes	1.25	1.18-1.32	< 0.001
History of gastrectomy (no)	Yes	1.46	0.88-2.43	0.142
Use of lipid-lowering agents (no)	Yes	1.02	0.99-1.06	0.159
Current smoker (no)	Yes	1.04	0.99-1.09	0.104
Walking or physical exercise > 1 h / wk (no)	Yes	0.91	0.94-0.89	< 0.001
BMI	1 kg/m ²	1.04	1.04-1.05	< 0.001
GGT	100 U/L	1.15	1.13-1.16	< 0.001
HbA1c	1%	1.03	1.01-1.04	0.001
LDL cholesterol	10 mg/dL	0.98	0.98-0.99	< 0.001
Systolic blood pressure	10 mm Hg	0.98	0.97-0.99	< 0.001
Triglycerides	100 mg/dL	1.04	1.02-1.06	< 0.001

BMI, body mass index; CI, confidence interval; GGT, gamma-glutamyl transpeptidase; HbA1c, hemoglobin A1c; HR, hazard ratio; LDL, low-density lipoprotein.

DISCUSSION

The three main causes of gallstone genesis are enhanced cholesterol nucleation, impaired gallbladder emptying with stasis, and intestinal hypomotility. Enhanced cholesterol nucleation is the most common type, accounting for 75-80% of occurrences, and is caused by impaired cholesterol metabolism [20]. Thus, metabolic syndrome and associated diseases such as higher BMI, hypertension, and diabetes mellitus have been widely reported to play a pivotal role in the pathogenesis of gallstone disease. The results of the present study are consistent with these previous studies.

This study demonstrates that increasing age, male sex, a variety of comorbidities (cerebrovascular disease, any malignancy, rheumatic disease, liver disease, congestive heart failure, chronic pulmonary disease, renal disorder, diabetes, hypertension, and pylori-infected gastritis), and several medical checkup items (BMI, γ-GT, HbA1c [%]) were closely associated with development of gallstones. Several of these factors have been identified in previous studies [21–23]; however, the present study is the first largescale cohort study to reveal the risk factors of rheumatic disease, malignancy, H. pyloriinfected gastritis, chronic pulmonary disease, and renal disorder.

Unlike previous reports, a higher prevalence of gallstones among men was observed in this study. Several classic epidemiologic studies have reported that pregnancy and female sex hormones place women at a higher risk [3-6]. The high prevalence of

gallstones among men in our study population is an indicator of a significant shift in the epidemiology of gallstone disease. One possible explanation for this is that the obesity rate among men has been on an upward trend in Japan since 2013. In 2019, 33.0% of men were considered overweight due to having an average body mass index of 25 or greater, 4.4% higher than in 2013. For women, the overall average was 22.3%, up 2.0% from 2013. A smaller proportion of women were obese compared to men across all age groups in 2019 [24]. Similarly, Sung et al. reported that the prevalence of asymptomatic cholelithiasis was higher in men than women over the age of 50 in Japan in 2017, concluding that this was due to the higher BMI, triglyceride, and fasting plasma glucose levels found in men than in women [25].

It had previously been suggested that patients with rheumatoid disease may be at increased risk for gallstones, but evidence for this association had been lacking before the present study. Our results are consistent with the suggestions of several past reports. Chen demonstrated a significant inverse relationship between systemic chronic inflammation and dyslipidemia in patients with rheumatoid disease [26]. In a study of 224 rheumatoid arthritis patients in Japan, Ito et al. found a significantly higher incidence of gallstones than in the general population, concluding that the chronic inflammatory state due to the condition altered lipid profile and gallbladder function, leading to the higher incidence [27]. In addition, other conditions such as low levels of physical activity or use of steroidal treatments by those with rheumatoid arthritis may be associated with an increased incidence of gallstones.

Among the few previous reports on the relationship between malignant disease and the development of cholelithiasis, Reimar W. et al. [28] found an association similar to the one found in the present study. Their population-based cohort study of 51,228 cancer patients reported that biliary obstruction due to malignant metastases to the liver in cancer patients, together with malnutrition and rapid weight loss in patients with malignant tumors, lead to a higher incidence of cholecystitis than in the general population. Thus, the specific conditions of patients with malignant diseases such as systemic inflammation and abnormal lipid metabolism appear to contribute to the development of cholelithiasis.

Interestingly, the present study found that H. pylori infection was positively correlated with the development of cholelithiasis. In a cross-sectional study, Takahashi et

al. [29] reported that H. pylori infection was positively correlated with the presence of gallstones. H. pylori has proven to be a major pathogen in gastric diseases such as chronic gastritis, gastric ulcers, duodenal ulcers, and gastric cancer [30]. Furthermore, H. pylori infection has also been reported to be associated with extra-gastric diseases such as dyslipidemia, type 2 diabetes, insulin resistance, metabolic syndrome, and increased bilirubin levels [31–35]. Given that *H. pylori* infection is related to these metabolic diseases, it may also be an indirect mediator of the gallbladder environment, leading to the development of gallstones.

This study also confirms that chronic lung disease with smoking as a risk factor increases the risk of cholelithiasis. There are several reports indicating that smoking is a risk factor for developing the disease [36,37], and the present study identifies chronic lung disease as a risk factor for it. However, little is known about the biological mechanisms by which these factors may cause the disease. One possibility is that the dozens of toxic compounds contained in tobacco smoke [37,38] may have a detrimental effect on the gallbladder. The relevant biological mechanisms need further elucidation.

This study also found a higher incidence of cholelithiasis in patients with chronic kidney disease. Several previous reports have also shown an association between renal disease and cholelithiasis [39]. Dysautonomia, which is common in patients with renal failure, impairs gallbladder motility, and renal failure increases biliary cholesterol and decreases primary bile acids in bile, making such patients more susceptible to cholelithiasis [40]. Thus, previous research found that several abnormalities related to renal function appear to promote gallstone formation, a finding consistent with that of the present study.

In addition, the present study found an association between gallstones and dementia. Miyamoto et al [41] found in a cross-sectional study that biliary sludge developed in older adults with dementia, which may have been due to the poor nutritional intake, immobility, and frailty commonly observed in dementia patients. This suggests that the development of cholelithiasis may be influenced by complex factors such as low levels of nutritional intake and physical activity.

This study also found trends for several factors that differ from those of previous reports. It did not find associations between the development of cholelithiasis and parenteral nutrition, spinal cord injury, or gastrectomy, likely due to the small number of

cases involving these factors. The discrepancy between the positive and negative hazard ratios for hypertensive complications and systolic blood pressure is likely to be related to a history of antihypertensive drug use.

The major strength of this study is its presentation of incidence trends in a recent 7.5-year period based on a large sample. However, this study also has several limitations. First, the incidence of gallstones was defined according to the International Classification of Diseases (Tenth Edition) coding, which has not yet been validated using medical record data. Secondly, age at onset could not be accurately ascertained, so age at diagnosis was used as a proxy. Finally, the study confirmed that enrollees with newly-diagnosed gallstones did not have gallstones during the one-year covariate assessment window. However, if a patient who already had gallstones did not use insurance for gallstone treatment during the baseline period, he or she may have been treated as a new onset patient. The definition of cholelithiasis used in this study includes patients who made an insurance claim for cholelithiasis at least once during the observation period, but patients with cholelithiasis who did not visit a healthcare provider could not be included in the study. Despite these limitations, this study provides novel evidence for the association between gallstone disease and a large number risk factors.

Conclusion

This study reveals that the risk of cholelithiasis in the general Japanese population is increased by male sex, cerebrovascular disease, malignancy, dementia, rheumatic disease, chronic pulmonary disease, hypertension, and H. pylori gastritis. These findings may contribute to efforts to reducing the incidence of cholelithiasis.

Author contributions

KH and EN contributed equally to this work. KH performed statistical analysis. KH and EN interpreted the data. KH wrote the draft of the manuscript. KH, EN, PH, SF and NO contributed to critical revision of the manuscript. All authors have read and approved the final version of the manuscript.

Acknowledgement

We thank Professor Yoshiki Miyachi of Kyoto University and Shizuoka Graduate

perpetuity.

It is made available under a CC-BY 4.0 International license .

University of Public Health for his useful comments and criticism.

Data availability statement

Based on a data use agreement with regional insurers in Shizuoka Prefecture, we are unable to make the analytical data accessible to readers.

Additional information

The authors declare no conflicts of interest. The Shizuoka Graduate University of Public Health conducts research projects on public health under contract to Shizuoka Prefecture, including this study.

References

- [1] Portincasa P, Moschetta A, Petruzzelli M, Palasciano G, Di Ciaula A, Pezzolla A. Gallstone disease: Symptoms and diagnosis of gallbladder stones. Best Pract Res Clin Gastroenterol 2006;20:1017–29.
- [2] Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver 2012;6:172–87.
- [3] Kimura Y, Takada T, Kawarada Y, Nimura Y, Hirata K, Sekimoto M, et al. Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007;14:15–26.
- [4] Reshetnyak VI. Concept of the pathogenesis and treatment of cholelithiasis. World J Hepatol 2012;4:18–34.
- [5] Attili AF, Carulli N, Roda E, Barbara B, Capocaccia L, Menotti A, et al. Epidemiology of gallstone disease in Italy: prevalence data of the Multicenter Italian Study on Cholelithiasis (M.I.COL.). Am J Epidemiol 1995;141:158–65.
- [6] Celaj S, Kourkoumpetis T. Gallstones in Pregnancy. JAMA 2021;325:2410.
- [7] Friedman GD, Kannel WB, Dawber TR. The epidemiology of gallbladder disease: observations in the Framingham Study. J Chronic Dis 1966;19:273–92.
- [8] Gebhard RL, Prigge WF, Ansel HJ, Schlasner L, Ketover SR, Sande D, et al. The role of gallbladder emptying in gallstone formation during diet-induced rapid weight loss. Hepatology 1996;24:544–8.
- [9] De Santis A, Attili AF, Ginanni Corradini S, Scafato E, Cantagalli A, De Luca C, et al. Gallstones and diabetes: a case-control study in a free-living population sample. Hepatology 1997;25:787–90.
- [10] Shabanzadeh DM, Sørensen LT, Jørgensen T. Determinants for gallstone formation a new data cohort study and a systematic review with meta-analysis. Scand J Gastroenterol 2016;51:1239–48.
- [11] Hansen NL, Brønden A, Nexøe-Larsen CC, Christensen AS, Sonne DP, Rehfeld JF, et al. Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study. Clin Transl Gastroenterol 2020;11:e00257.
- [12] Lapidus A, Bångstad M, Aström M, Muhrbeck O. The prevalence of gallstone

perpetuity.
It is made available under a CC-BY 4.0 International license .

- disease in a defined cohort of patients with Crohn's disease. Am J Gastroenterol 1999;94:1261–6.
- [13] Parente F, Pastore L, Bargiggia S, Cucino C, Greco S, Molteni M, et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007;45:1267–74.
- [14] Nightingale JM, Lennard-Jones JE, Gertner DJ, Wood SR, Bartram CI. Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones, but does not change high prevalence of gall stones in patients with a short bowel. Gut 1992;33:1493–7.
- [15] Thijs C, Knipschild P. Oral contraceptives and the risk of gallbladder disease: a meta-analysis. Am J Public Health 1993;83:1113–20.
- [16] Inoue K, Fuchigami A, Higashide S, Sumi S, Kogire M, Suzuki T, et al. Gallbladder sludge and stone formation in relation to contractile function after gastrectomy. A prospective study. Ann Surg 1992;215:19–26.
- [17] Tsunoda K, Shirai Y, Hatakeyama K. Prevalence of cholesterol gallstones positively correlates with per capita daily calorie intake. Hepatogastroenterology 2004;51:1271–4.
- [18] Nakatani E, Tabara Y, Sato Y, Tsuchiya A, Miyachi Y. Data resource profile of Shizuoka Kokuho Database (SKDB) using integrated health- and care-insurance claims and health checkups: the Shizuoka Study. J Epidemiol 2021. https://doi.org/10.2188/jea.JE20200480.
- [19] Ferkingstad E, Oddsson A, Gretarsdottir S, Benonisdottir S, Thorleifsson G, Deaton AM, et al. Genome-wide association meta-analysis yields 20 loci associated with gallstone disease. Nat Commun 2018;9:5101.
- [20] Di Ciaula A, Wang DQ-H, Portincasa P. An update on the pathogenesis of cholesterol gallstone disease. Curr Opin Gastroenterol 2018;34:71–80.
- [21] Faillie J-L, Yu OH, Yin H, Hillaire-Buys D, Barkun A, Azoulay L. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus. JAMA Intern Med 2016;176:1474–81.
- [22] Zhao S-F, Wang A-M, Yu X-J, Wang L-L, Xu X-N, Shi G-J. Association between gallstone and cardio-cerebrovascular disease: Systematic review and meta-analysis. Exp Ther Med 2019;17:3092–100.
- [23] Fairfield CJ, Wigmore SJ, Harrison EM. Gallstone Disease and the Risk of Cardiovascular Disease. Sci Rep 2019;9:5830.
- [24] Ministry of Health, Labour and Welfare, Japan. National Health and Nutrition Survey in 2019 n.d. http://www.mhlw.go.jp/bunya/kenkou/kenkou_eiyou_chousa.html (accessed 2022/july/05).
- [25] Kim SB, Kim KH, Kim TN, Heo J, Jung MK, Cho CM, et al. Sex differences in prevalence and risk factors of asymptomatic cholelithiasis in Korean health screening examinee: A retrospective analysis of a multicenter study. Medicine 2017;96:e6477.
- [26] Chen W, Wang Q, Zhou B, Zhang L, Zhu H. Lipid Metabolism Profiles in Rheumatic Diseases. Front Pharmacol 2021;12:643520.
- [27] Ito S, Hasegawa H, Nozawa S, Ishikawa H, Tohyama C, Nakazono K, et al. Gallstones in patients with rheumatoid arthritis. J Rheumatol 1999;26:1458–66.
- [28] Thomsen RW, Thomsen HF, Nørgaard M, Cetin K, McLaughlin JK, Tarone RE, et

perpetuity.

It is made available under a CC-BY 4.0 International license .

- al. Risk of cholecystitis in patients with cancer: a population-based cohort study in Denmark. Cancer 2008;113:3410–9.
- [29] Takahashi Y, Yamamichi N, Shimamoto T, Mochizuki S, Fujishiro M, Takeuchi C, et al. Helicobacter pylori infection is positively associated with gallstones: a large-scale cross-sectional study in Japan. J Gastroenterol 2014;49:882–9.
- [30] Alexander SM, Retnakumar RJ, Chouhan D, Devi TNB, Dharmaseelan S, Devadas K, et al. Helicobacter pylori in Human Stomach: The Inconsistencies in Clinical Outcomes and the Probable Causes. Front Microbiol 2021;12:713955.
- [31] Satoh H, Saijo Y, Yoshioka E, Tsutsui H. Helicobacter Pylori infection is a significant risk for modified lipid profile in Japanese male subjects. J Atheroscler Thromb 2010;17:1041–8.
- [32] Hsieh M-C, Wang SSW, Hsieh Y-T, Kuo F-C, Soon M-S, Wu D-C. Helicobacter pylori infection associated with high HbA1c and type 2 diabetes. Eur J Clin Invest 2013;43:949–56.
- [33] Zhou X, Liu W, Gu M, Zhou H, Zhang G. Helicobacter pylori infection causes hepatic insulin resistance by the c-Jun/miR-203/SOCS3 signaling pathway. J Gastroenterol 2015;50:1027–40.
- [34] Refaeli R, Chodick G, Haj S, Goren S, Shalev V, Muhsen K. Relationships of H. pylori infection and its related gastroduodenal morbidity with metabolic syndrome: a large cross-sectional study. Sci Rep 2018;8:4088.
- [35] Zhao M-M, Krebs J, Cao X, Cui J, Chen D-N, Li Y, et al. Helicobacter pylori infection as a risk factor for serum bilirubin change and less favourable lipid profiles: a hospital-based health examination survey. BMC Infect Dis 2019;19:157.
- [36] Katsika D, Tuvblad C, Einarsson C, Lichtenstein P, Marschall H-U. Body mass index, alcohol, tobacco and symptomatic gallstone disease: a Swedish twin study. J Intern Med 2007;262:581–7.
- [37] Aune D, Vatten LJ, Boffetta P. Tobacco smoking and the risk of gallbladder disease. Eur J Epidemiol 2016;31:643–53.
- [38] Anglo-Dutch Nicotine Intestinal Study Group, Rhodes M, Zijlastra FJ, Bradburn DM, Srivastava ED, van Dijk APM, et al. Effect of Nicotine on Gallbladder Bile. Can J Gastroenterol 1900;8:304548.
- [39] Park SK, Jung JY, Oh C-M, Kim M-H, Ha E, Lee D-Y, et al. The Level of Urine Dipstick Proteinuria and Its Relation to the Risk of Incident Cholelithiasis. J Epidemiol 2021;31:59–64.
- [40] Elsadek HM, Qasem AA, Farag SE, Al Sowy AM, Ebouda FM, Alghamdi FS. Gallbladder dysfunction and gallstone prevalence in patients with chronic kidney disease. Is there a difference between predialysis and hemodialysis patients? A multi-center Study. Int J Adv Res (Indore) 2014;2:842–8.
- [41] Miyamoto T, Ebihara T, Kozaki K. The association between eating difficulties and biliary sludge in the gallbladder in older adults with advanced dementia, at end of life. PLoS One 2019;14:e0219538.

FIGURES

Figure Legends

Figure 1. Study schema


Cohort entry is defined as the date of registration with the health insurance provider or April 1, 2012, whichever occurred later. The index date is defined as the initial date of annual health checkups with ≥ 1 year continuous subscribership to the health insurance system. "Follow-up period" is defined as the interval between the index date and (1) the end of the study (September 30, 2020) or (2) the withdrawal date from the health insurance system, whichever occurred first.


Figure 2. Flow chart of study

Supporting information

S1 Table. Spearman's correlation matrix

ALT, Alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GFR, glomerular filtration rate; GGT, gamma-glutamyl transpeptidase; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein





Participants Flow